Literature DB >> 22544209

Spectrum of F9 mutations in Chinese haemophilia B patients: identification of 20 novel mutations.

Tingting Yu1, Jing Dai, Hongjing Liu, Qiulan Ding, Yelin Lu, Hongli Wang, Xuefeng Wang, Qihua Fu.   

Abstract

AIMS: Haemophilia B (HB) is an X-linked recessive haemorrhagic disorder caused by F9 mutations. In this study, we performed molecular analysis of 107 Chinese HB patients and analysed the F9 mutation spectrum of Chinese HB patients.
METHODS: 107 Chinese HB patients were enrolled in this study. Direct sequencing of the whole F9 or mutation scanning of exon 1 to exon 7 by high resolution melting (HRM) curve analysis combined with direct sequencing of exon 8 was used to identify the mutations in these patients.
RESULTS: 78 different F9 mutations were identified in the 107 HB patients. The mutations were composed of 50 missense mutations, 14 nonsense mutations, nine small deletions, three splice site mutations and two small insertions. Forty-three of 78 mutations were located in factor IX (FIX) catalytic domain. Among the 78 mutations, 20 have not been previously reported.
CONCLUSIONS: The F9 mutations were heterogenous and the missense mutations were the most prevalent gene defects in Chinese HB patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544209     DOI: 10.1097/PAT.0b013e328353443d

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  9 in total

1.  High resolution melting for F9 gene mutation analysis in patients with haemophilia B.

Authors:  Roberta Salviato; Donata Belvini; Paolo Radossi; Giuseppe Tagariello
Journal:  Blood Transfus       Date:  2018-02-28       Impact factor: 3.443

2.  Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients.

Authors:  Qiuya Lu; Likui Yang; Chandrashekhara Manithody; Xuefeng Wang; Alireza R Rezaie
Journal:  Biochemistry       Date:  2015-06-10       Impact factor: 3.162

3.  Mutation analysis of a cohort of US patients with hemophilia B.

Authors:  Tengguo Li; Connie H Miller; Jennifer Driggers; Amanda B Payne; Dorothy Ellingsen; W Craig Hooper
Journal:  Am J Hematol       Date:  2014-03-03       Impact factor: 10.047

Review 4.  Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs.

Authors:  Timothy C Nichols; Margaret H Whitford; Valder R Arruda; Hansell H Stedman; Mark A Kay; Katherine A High
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-12

5.  Mutational Profiles of F8 and F9 in a Cohort of Haemophilia A and Haemophilia B Patients in the Multi-ethnic Malaysian Population.

Authors:  Maimiza Zahari; Siti Aishah Sulaiman; Zulhabri Othman; Yasmin Ayob; Faraizah Abd Karim; Rahman Jamal
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-09-01       Impact factor: 2.576

6.  Microfluidic hemophilia models using blood from healthy donors.

Authors:  Xinren Yu; Karen A Panckeri; Lacramioara Ivanciu; Rodney M Camire; Carmen H Coxon; Adam Cuker; Scott L Diamond
Journal:  Res Pract Thromb Haemost       Date:  2019-12-02

Review 7.  Molecular Insights into Determinants of Translational Readthrough and Implications for Nonsense Suppression Approaches.

Authors:  Silvia Lombardi; Maria Francesca Testa; Mirko Pinotti; Alessio Branchini
Journal:  Int J Mol Sci       Date:  2020-12-11       Impact factor: 5.923

8.  Mutation analysis and characterisation of F9 gene in haemophilia- B population of India.

Authors:  Sujayendra Kulkarni; Rajat Hegde; Smita Hegde; Suyamindra S Kulkarni; Suresh Hanagvadi; Kusal K Das; Sanjeev Kolagi; Pramod B Gai; Rudragouda Bulagouda
Journal:  Blood Res       Date:  2021-12-31

9.  Characterization of missense mutations in the signal peptide and propeptide of FIX in hemophilia B by a cell-based assay.

Authors:  Wenwen Gao; Yaqi Xu; Hongli Liu; Meng Gao; Qing Cao; Yiyi Wang; Longteng Cui; Rong Huang; Yan Shen; Sanqiang Li; Haiping Yang; Yixiang Chen; Chaokun Li; Haichuan Yu; Weikai Li; Guomin Shen
Journal:  Blood Adv       Date:  2020-08-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.